PhoreMost

MRI showing glioblastoma
#Brain cancer #Clinical trial #PhoreMost

PhoreMost advances brain cancer programme to trial  

PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer.  The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial.  PMC-001 is… Read More

#Cancer Research #News

Drug screening in laboratory
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Collaboration #Drug targets #High throughput screening #Partnership #Phenotyping #PhoreMost #ThinkCyte

New research collaboration to advance AI based drug discovery

PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).  The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry. … Read More

#News

Man using microscope in lab
#Collaboration #Phenotyping #PhoreMost #Protein binders #Therapeutic targets

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration… Read More

#Business & Investment #News

#Drug discovery #Pharmaceutical industry #Phenotyping #PhoreMost #Roche

PhoreMost and Roche enter drug discovery partnership

Roche and UK-based biopharmaceutical company PhoreMost have agreed to a multi-project target discovery collaboration. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche. Novel targets identified… Read More

#Business & Investment #News